{
    "clinical_study": {
        "@rank": "52110", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/PCa arm post radiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "DCVAC/PCa Experimental therapy post radiotherapy"
            }, 
            {
                "arm_group_label": "Standard radiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard care"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/PCa added after radical primary\n      prostatectomy can improve PSA progression times within 5 years for patients with high risk\n      localized Prostate Cancer."
        }, 
        "brief_title": "Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Treatment post radical primary prostatectomy Treatment post standard radiotherapy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male 18 years and older\n\n          -  Histologically confirmed localized prostate cancer of high risk or very high risk\n             fulfilling at least one of the following: T3-T4 stage or Gleason Score 8-10 or PSA\n             level above 20 ng/ml\n\n          -  Indication for prostate cancer radical radiotherapy\n\n          -  Neo-adjuvant androgen androgen-deprivation therapy due to prostate cancer using\n             Luteinizing-hormone-releasing hormone (LHRH) analogues ongoing for at least two\n             months and not longer than 12 months prior randomization\n\n          -  Eastern Cooperative Oncology Group (ECOG)  0-2\n\n        Exclusion Criteria:\n\n          -  Primary surgical treatment of prostate cancer\n\n          -  Prior or ongoing chemotherapy for prostate cancer\n\n          -  Participation in other clinical study or administration of other evaluated drug\n             within 30 day prior screening\n\n          -  Unresolved lasting obstruction of urinary system\n\n          -  Other uncontrolled inter-current illness\n\n          -  Treatment with immunotherapy against Prostate Cancer\n\n          -  Clinically significant cardiovascular disease\n\n          -  History of primary immunodeficiency\n\n          -  Active autoimmune disease requiring treatment"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107430", 
            "org_study_id": "SP004", 
            "secondary_id": "2011-004967-65"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DCVAC/PCa arm post radiotherapy", 
                    "Standard radiotherapy"
                ], 
                "description": "DCVAC/PCa arm post radiotherapy", 
                "intervention_name": "DCVAC/PCa", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Standard radiotherapy", 
                "description": "radiotherapy", 
                "intervention_name": "Standard radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "Prostate Cancer (PCa)", 
            "Biological, Vaccine"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jihlava", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novy Jicin", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 10", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 8", 
                        "country": "Czech Republic"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Localized High-risk Prostate Cancer After Primary Radiotherapy", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Prostate Specific Antigen (PSA) failures in 5 years", 
            "safety_issue": "No", 
            "time_frame": "260 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Patients without use of salvage therapy  within 5 years", 
                "safety_issue": "No", 
                "time_frame": "260 weeks"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "0, 2, 11, 13, 17, 21, 25, 29, 33, 37, 41, 45, 57, 69, 81, 93, 105, 166, 218, 260 weeks"
            }, 
            {
                "measure": "Proportion of Patients without Objective disease progression within 5 years", 
                "safety_issue": "No", 
                "time_frame": "260 weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}